Olema Oncology
Brian Rich is an accomplished scientist with extensive experience in medicinal chemistry and drug design. Currently serving as a Scientist I at Olema Oncology, Brian Rich supports programs focused on estrogen receptor alpha and kinase targets, initiating computational chemistry efforts and applying structure-based drug design. Prior roles include Principal Research Associate and Associate Scientist at BlackThorn Therapeutics, where Brian Rich contributed to CNS drug development, and Senior Research Associate at Nanosyn, specializing in organic process development. Brian Rich began a research career at UC Santa Barbara in the Lipshutz Group, developing innovative synthetic methodologies with a focus on green chemistry. Academic qualifications include a BS in Chemistry and Biochemistry from UC Santa Barbara, complemented by studies at the University of Oxford and the University of Pennsylvania.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.